The recent rise in option deals has been driven at least in part by the lack of financing or exit alternatives. According to seasoned dealmakers, they are not just a short-term symptom of a buyers’ market, but potentially a viable opportunity for biotechs to partner with deep-pocketed pharma companies. Come out to the next Biotech Forum and hear seasoned biopharma dealmakers from GSK, Eli Lilly, and Novartis Option Fund discuss option based deals. How do they work and how can a startup benefit from one?

Speakers:

• David Donabedian, VP, Business Development, Alternative Discovery & Development, GSK
• Mark A. Miller, VP of Corporate Business Development, Eli Lilly and Company
• Lauren Silverman, Managing Director, Novartis Option Fund
• Paul Torrey, Life Sciences Industry Practice, Deloitte